Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

Commitments and Contingencies (Details)									1 Months Ended			3 Months Ended	9 Months Ended	12 Months Ended
Commitments and Contingencies (Details)	Mar. 28, 2024 USD ($)	Mar. 27, 2024 USD ($)	Oct. 27, 2023 USD ($)	Jun. 21, 2021 USD ($)	May 28, 2021 USD ($)	Mar. 25, 2021 USD ($)	Feb. 03, 2020 USD ($)	Jul. 15, 2019	Oct. 31, 2024 USD ($)	Apr. 30, 2024 USD ($)	Jul. 31, 2019 USD ($)	Mar. 31, 2020 USD ($) milestone	Sep. 30, 2024 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2018 unit $ / shares	Oct. 08, 2024 USD ($)	Dec. 31, 2023 USD ($)	Feb. 03, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 09, 2021 USD ($)
Other Commitments [Line Items]
Contingent consideration													$ 5,000,000				$ 0
Payment received											$ 2,000,000
Period after public launch to terminate agreement											3 years
Percentage of net present value of royalty payments											75.00%
Aevi
Other Commitments [Line Items]
Milestone payment contingent consideration													0
AlmataBio Transaction
Other Commitments [Line Items]
Payments to acquire productive assets	$ 7,500,000									$ 7,500,000			7,500,000
Milestone payment due upon first patient dosed in a Phase 2 trial													5,000,000
Aevi
Other Commitments [Line Items]
Number of milestones \| milestone												2
Milestone payment due upon first patient dosed in a Phase 2 trial												$ 6,500,000
AVTX-301 Out-License
Other Commitments [Line Items]
Licensed product expiration term					10 years
Milestone One \| AlmataBio Transaction
Other Commitments [Line Items]
Milestone payment due upon first patient dosed in a Phase 2 and 3 trial	5,000,000
Milestone One \| AlmataBio Transaction \| Subsequent Event
Other Commitments [Line Items]
Milestone payment due upon first patient dosed in a Phase 2 and 3 trial																$ 5,000,000
Milestone One \| Aevi
Other Commitments [Line Items]
Milestone payment due upon first patient dosed in a Phase 2 and 3 trial																		$ 2,000,000.0
Milestone Two \| AlmataBio Transaction
Other Commitments [Line Items]
Milestone payment due upon first patient dosed in a Phase 2 and 3 trial	$ 15,000,000
Milestone Two \| AlmataBio Transaction \| Subsequent Event
Other Commitments [Line Items]
Milestone payment due upon first patient dosed in a Phase 2 and 3 trial																$ 15,000,000
Milestone Two \| Aevi
Other Commitments [Line Items]
Milestone payment due upon first patient dosed in a Phase 2 and 3 trial																		$ 4,500,000
Milestone Two \| AVTX-009
Other Commitments [Line Items]
Contingent consideration													5,000,000
Milestone Three \| AVTX-009 \| Subsequent Event
Other Commitments [Line Items]
Collaborative agreement, milestone payment									$ 5,000,000
Lilly License Agreement \| AVTX-009 Lilly License Agreement
Other Commitments [Line Items]
Milestone payments		$ 70,000,000
Maximum aggregate milestone payment		$ 650,000,000
License agreement term		120 days
Lilly License Agreement \| AVTX-009 Lilly License Agreement \| Minimum
Other Commitments [Line Items]
License agreement royalties		5.00%
Lilly License Agreement \| AVTX-009 Lilly License Agreement \| Maximum
Other Commitments [Line Items]
License agreement royalties		15.00%
Kyowa Kirin Co., Ltd. (KKC) \| Minimum \| Contract Termination
Other Commitments [Line Items]
License agreement term						6 months
Kyowa Kirin Co., Ltd. (KKC) \| Maximum \| Contract Termination
Other Commitments [Line Items]
License agreement term						12 months
Kyowa Kirin Co., Ltd. (KKC) \| AVTX-002 KKC License Agreement
Other Commitments [Line Items]
Upfront license fee						$ 10,000,000
Research and development expense													0
Cumulative expense recognized to date													0
Kyowa Kirin Co., Ltd. (KKC) \| AVTX-002 KKC License Agreement \| Milestone One
Other Commitments [Line Items]
Maximum aggregate milestone payment						112,500,000
Kyowa Kirin Co., Ltd. (KKC) \| AVTX-002 KKC License Agreement \| Milestone Two
Other Commitments [Line Items]
Maximum aggregate milestone payment						$ 75,000,000
CHOP License Agreement
Other Commitments [Line Items]
Collaborative arrangement, royalty term							15 years
CHOP License Agreement \| Contract Termination
Other Commitments [Line Items]
License agreement term							6 months
CHOP License Agreement \| AVTX-002 KKC License Agreement
Other Commitments [Line Items]
Maximum aggregate milestone payment													900,000
Upfront license fee							$ 500,000
Payments for legal settlements														$ 1,000,000
License fee							$ 200,000
Sanford Burnham Prebys Medical Discovery Institute \| Contract Termination
Other Commitments [Line Items]
License agreement term				90 days
Sanford Burnham Prebys Medical Discovery Institute \| AVTX-008 Sanford Burnham Prebys License Agreement
Other Commitments [Line Items]
Upfront license fee				$ 400,000
Research and development expense													0
Cumulative expense recognized to date													0
License fee				40,000															$ 100,000
Patent costs				$ 500,000
Sanford Burnham Prebys Medical Discovery Institute \| AVTX-008 Sanford Burnham Prebys License Agreement \| Minimum
Other Commitments [Line Items]
License agreement royalties				10.00%
Sanford Burnham Prebys Medical Discovery Institute \| AVTX-008 Sanford Burnham Prebys License Agreement \| Maximum
Other Commitments [Line Items]
License agreement royalties				20.00%
Sanford Burnham Prebys Medical Discovery Institute \| AVTX-008 Sanford Burnham Prebys License Agreement \| Milestone One
Other Commitments [Line Items]
Maximum aggregate milestone payment				$ 24,200,000
Sanford Burnham Prebys Medical Discovery Institute \| AVTX-008 Sanford Burnham Prebys License Agreement \| Milestone Two
Other Commitments [Line Items]
Maximum aggregate milestone payment				$ 50,000,000
Astellas Pharma, Inc. (Astellas)
Other Commitments [Line Items]
License agreement term								60 days
Astellas Pharma, Inc. (Astellas) \| AVTX-006
Other Commitments [Line Items]
Licensed product expiration term								10 years
Astellas Pharma, Inc. (Astellas) \| AVTX-006 Astellas License Agreement
Other Commitments [Line Items]
Maximum aggregate milestone payment													5,500,000
Upfront license fee													500,000
Research and development expense													0
Cumulative expense recognized to date													500,000
Alto \| AVTX-301 Out-License
Other Commitments [Line Items]
Maximum proceeds from milestones					$ 18,600,000
Revenue recognized from milestones to date													0
ES \| AVTX-406 License Assignment
Other Commitments [Line Items]
Revenue recognized from milestones to date													$ 0
ES \| Milestone One \| AVTX-406 License Assignment
Other Commitments [Line Items]
Maximum proceeds from milestones																				$ 6,000,000
ES \| Milestone Two \| AVTX-406 License Assignment
Other Commitments [Line Items]
Maximum proceeds from milestones																				$ 20,000,000
AUG Therapeutics, LLC \| Purchase Agreement \| AVTX-800 Series Asset Sale
Other Commitments [Line Items]
Upfront payment paid			$ 200,000
Asset acquisition consideration transferred, liabilities			$ 400,000
Contingent milestone upfront payment percentage			0.20
Contingent milestone payment			$ 15,000,000
Maximum potential payments			$ 45,000,000
TRIS Pharma \| Karbinal Agreement
Other Commitments [Line Items]
Minimum quantity required \| unit															70,000
Make whole payment per unit (in dollars per share) \| $ / shares															$ 30